- Home
- DHIL vs ATAI Comparison
DHIL vs ATAI Comparison
Compare DHIL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- ATAI
- Stock Information
- Founded
- DHIL 1990
- ATAI 2018
- Country
- DHIL United States
- ATAI Germany
- Employees
- DHIL N/A
- ATAI N/A
- Industry
- DHIL Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- DHIL Finance
- ATAI Health Care
- Exchange
- DHIL Nasdaq
- ATAI Nasdaq
- Market Cap
- DHIL 386.7M
- ATAI 444.7M
- IPO Year
- DHIL 1995
- ATAI 2021
- Fundamental
- Price
- DHIL $137.45
- ATAI $2.48
- Analyst Decision
- DHIL
- ATAI Strong Buy
- Analyst Count
- DHIL 0
- ATAI 3
- Target Price
- DHIL N/A
- ATAI $10.50
- AVG Volume (30 Days)
- DHIL 47.4K
- ATAI 2.7M
- Earning Date
- DHIL 07-29-2025
- ATAI 08-12-2025
- Dividend Yield
- DHIL 4.38%
- ATAI N/A
- EPS Growth
- DHIL 0.69
- ATAI N/A
- EPS
- DHIL 14.79
- ATAI N/A
- Revenue
- DHIL $151,916,411.00
- ATAI $1,863,000.00
- Revenue This Year
- DHIL N/A
- ATAI $554.22
- Revenue Next Year
- DHIL N/A
- ATAI N/A
- P/E Ratio
- DHIL $9.29
- ATAI N/A
- Revenue Growth
- DHIL 9.28
- ATAI 572.56
- 52 Week Low
- DHIL $122.32
- ATAI $1.03
- 52 Week High
- DHIL $173.25
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- DHIL 45.49
- ATAI 66.50
- Support Level
- DHIL $134.01
- ATAI $2.06
- Resistance Level
- DHIL $146.60
- ATAI $2.55
- Average True Range (ATR)
- DHIL 3.14
- ATAI 0.20
- MACD
- DHIL -0.44
- ATAI -0.02
- Stochastic Oscillator
- DHIL 34.39
- ATAI 72.41
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.